Lectura interpretada del antibiograma: una necesidad clínica

Cantón, 2002, Lectura interpretada del antibiograma: ¿ejercicio intelectual o necesidad clínica?, Enferm Infecc Microbiol Clin, 20, 176, 10.1016/S0213-005X(02)72783-3 Cornaglia, 2004, European recommendations for antimicrobial resistance surveillance, Clin Microbiol Infect, 10, 349, 10.1111/j.1198-743X.2004.00887.x Cantón, 2009, Consumo de antimicrobianos y resistencia en el hospital: una relación difícil de medir y compleja de interpretar, Enferm Infecc Microbiol Clin, 27, 437, 10.1016/j.eimc.2009.04.004 Ambrose, 2006, Monte Carlo simulation in the evaluation of susceptibility breakpoints: Predicting the future: Insights from the Society of Infectious Diseases Pharmacists, Pharmacotherapy, 26, 129, 10.1592/phco.2006.26.1.129 Turnidge, 2007, Setting and revising antibacterial susceptibility breakpoints, Clin Microbiol Revs, 20, 391, 10.1128/CMR.00047-06 Kahlmeter, 2003, European harmonisation of MIC breakpoints for antimicrobial susceptibility testing of bacteria, J Antimicrob Chemother, 52, 145, 10.1093/jac/dkg312 Jorgensen, 2009, Antimicrobial susceptibility testing: A review of general principles and contemporary practices, Clinical Infectious Diseases, 49, 1749, 10.1086/647952 Van Eldere, 2005, Changing needs, opportunities and constraints for the 21st century microbiology laboratory, Clin Microbiol Infect, 11, 15, 10.1111/j.1469-0691.2005.01084.x Poupard, 1994, The evolution of antimicrobial susceptibility testing methods, 3 2000, Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos. (MENSURA). Recomendaciones del grupo MENSURA para la selección de antimicrobianos en el estudio de la sensibilidad y criterios de interpretación del antibiograma, Rev Esp Quimioter, 13, 73 Ferraro, 2001, Should we reevaluate antibiotic breakpoints?, Clin Infect Dis, 33, S240, 10.1086/321852 Comité de l’Antibiogramme de la Société Française de Microbiologie. Recomendations 2009. 2009 [consultado 20/12/2010]. Disponible en: http://www.sfm.asso.frwww.sfm.asso.fr 2001, Antimicrobial susceptibility testing: BSAC Working Party Report, J Antimicrob Chemother, 48 Baquero, 1990, European standards for antibiotic susceptibility testing: Towards a theoretical consensus, Eur J Clin Microbiol Infect Dis, 9, 492, 10.1007/BF01964289 International Organization for Standardization (ISO). 2006 Clinical laboratory testing and in vitro diagnostic diagnostic test systems – Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices-Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.International Standard 20776-1, ISO, Ginebra. Turnidge, 2006, Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values, Clin Microbiol Infect, 12, 418, 10.1111/j.1469-0691.2006.01377.x Courvalin, 1992, Interpretive reading of antimicrobial susceptibility test, ASM News, 58, 368 Livermore, 2001, Interpretative reading: Recognizing the unusual and inferring resistance mechanisms from resistance phenotypes, J Antimicrob Chemother, 48, 87, 10.1093/jac/48.suppl_1.87 Cantón, 2005, Role of the microbiology laboratory in infectious disease surveillance, alert and response, Clin Microbiol Infect, 11, 3, 10.1111/j.1469-0691.2005.01081.x Baquero, 2010, Public-health microbiology, a challenge for Europe, Clin Microbiol Infect, 10.1111/j.1469-0691.2009.03126.x Medeiros, 1974, Characterization and prevalence of the different mechanisms of resistance to β-lactam antibiotics in clinical isolates of Escherichia coli, Antimicrob Agents Chemother, 6, 791, 10.1128/AAC.6.6.791 Loza Fernández de Bobadilla, 1988, Evolución de la actividad de cefotaxima en 6 años y fenotipos de sensibilidad en Enterobacteriaceae, Enf Infec Microbiol Clin, 6, 3 Shah, 1983, Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than third generation cephalosporins, J Antimicrob Chemother, 11, 597, 10.1093/jac/11.6.597 Chambers, 1990, Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus, J Infect Dis, 162, 705, 10.1093/infdis/162.3.705 Page, 2006, Anti-MRSA beta-lactams in development, Curr Opin Pharmacol, 5, 480, 10.1016/j.coph.2006.06.002 Davidson, 2002, Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia, N Engl J Med, 346, 747, 10.1056/NEJMoa012122 Helms, 2002, Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium, Emerg Infect Dis, 8, 490, 10.3201/eid0805.010267 Slinger, 2004, Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: A case series, BMC Infect Dis, 4, 36, 10.1186/1471-2334-4-36 Kadhiravan, 2005, Clinical outcomes in typhoid fever: Adverse impact of infection with nalidixic acid-resistant Salmonella typhi, BMC Infect Dis, 5, 37, 10.1186/1471-2334-5-37 Martel, 1977, 2”-O-phosphorylation of gentamicin components by a Staphylococcus aureus strain carrying a plasmid, Antimicrob Agents Chemother, 12, 26, 10.1128/AAC.12.1.26 Asseray, 2002, Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model, Antimicrob Agents Chemother, 46, 1591, 10.1128/AAC.46.5.1591-1593.2002 Clinical and Laboratory Standards Institute. Performance and standards for antimicrobial susceptibility testing. Nineteen informational supplement. Document M100-S20. 2010. Wayne, PA. Andes, 2005, Treatment of infections with ESBL-producing organisms: Pharmacokinetic and pharmacodynamic considerations, Clin Microbiol Infect, 11, 10, 10.1111/j.1469-0691.2005.01265.x Bin, 2006, Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli, Diagn Microbiol Infect Dis, 56, 351, 10.1016/j.diagmicrobio.2006.06.015 Bhat, 2007, Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms, Antimicrob Agents Chemother, 51, 4390, 10.1128/AAC.01487-06 Courvalin, 1996, Interpretive reading of in vitro antibiotic susceptibility tests (the antibiogramme), Clin Microbiol Infect, 2, S26, 10.1111/j.1469-0691.1996.tb00872.x Macgowan, 2008, BSAC working parties on resistance surveillance. Clinical implications of antimicrobial resistance for therapy, J Antimicrob Chemother, 62, ii105, 10.1093/jac/dkn357 Moise-Broder, 2004, Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy, Clin Infect Dis, 38, 1700, 10.1086/421092 Soriano, 2008, Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, 46, 193, 10.1086/524667 Musta, 2009, Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: Trends over 11 years, J Clin Microbiol, 47, 1640, 10.1128/JCM.02135-08 Aarestrup, 2003, Is it time to change fluoroquinolone breakpoints for Salmonella spp.?, Antimicrob Agents Chemother, 47, 827, 10.1128/AAC.47.2.827-829.2003 Crump, 2008, Clinical response and outcome of infection with Salmonella enterica serotype typhi with decreased susceptibility to fluoroquinolones: A United States foodnet multicenter retrospective cohort study, Antimicrob Agents Chemother, 52, 1278, 10.1128/AAC.01509-07 Navarro, 2002, Lectura interpretada del antibiograma en enterobacterias, Enf Infec Microbiol Clin, 20, 225, 10.1016/S0213-005X(02)72796-1 Davis SL, Neuhauser MM, McKinnon PS. Quinolones. En: Yu VL, Edwards G, MaKinnon PS, Peloquin C, Morse GD, editores. Antimicrobial therapy and vaccines. 2 ed. Pittsburgh, PA (EEUU): 2005. pp. 337–66. Cattoir, 2009, Plasmid-mediated quinolone resistance in gram-negative bacterial species: An update, Curr Med Chem, 16, 1028, 10.2174/092986709787581879 Poirel, 2006, In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase, Antimicrob Agents Chemother, 50, 1525, 10.1128/AAC.50.4.1525-1527.2006 Poirel, 2008, Is plasmid-mediated quinolone resistance a clinically significant problem?, Clin Microbiol Infect, 14, 295, 10.1111/j.1469-0691.2007.01930.x Murray, 2000, Vancomycin-resistant enterococcal infections, N Engl J Med, 342, 710, 10.1056/NEJM200003093421007 Weisblum, 1998, Macrolide resistance, Drug Res Updates, 1, 29, 10.1016/S1368-7646(98)80212-4 Cornaglia, 1995, Relative importances of outer membrane permeability and group 1 β-lactamase as determinants of meropenem and imipenem activities against Enterobacter cloacae, Antimicrob Agents Chemother, 39, 350, 10.1128/AAC.39.2.350 Jones, 2009, Zyvox Annual Appraisal of Potency and Spectrum program: Linezolid surveillance program results for 2008, Diagn Microbiol Infect Dis, 65, 404, 10.1016/j.diagmicrobio.2009.10.001 Long, 2006, The Cfr rRNA methyltransferase confers resistance to Phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics, Antimicrob Agents Chemother, 50, 2500, 10.1128/AAC.00131-06 Tato, 2007, Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: Toward endemicity?, Clin Infect Dis, 45, 1171, 10.1086/522288 Vatopoulos, 2008, High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence, Euro Surveill, 24, 13 Appelbaum, 2007, Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA), Int J Antimicrob Agents, 30, 398, 10.1016/j.ijantimicag.2007.07.011 Livermore, 2002, Multicenter evaluation of the VITEK 2 Advance Expert System for interpretive reading of antimicrobial resistance tests, J Antimicrobial Chemother, 49, 289, 10.1093/jac/49.2.289 Cantón, 2007, Recomendaciones para la selección de antimicrobianos y concentraciones en el estudio de la sensibilidad in vitro con sistemas automáticos y semiautomáticos, Enferm Infecc Microbiol Clin, 25, 394, 10.1157/13106965 Wilson, 2008, Assuring the quality of clinical microbiology test results, Clin Infect Dis, 47, 1077, 10.1086/592071 Livermore, 1995, β-lactamases in laboratory and clinical resistance, Clin Microbiol Rev, 8, 557, 10.1128/CMR.8.4.557 Miller, 1997, The most frequent aminoglycoside resistance mechanisms changes with time and geographic area- a reflection of aminoglycoside usage patterns?, Clin Infect Dis, 24, S46, 10.1093/clinids/24.Supplement_1.S46 Poole, 2001, Multidrug resistance in gram-negative bacteria, Curr Opin Microbiol, 4, 500, 10.1016/S1369-5274(00)00242-3 Hooper, 2000, Mechanisms of action and resistance of older and newer fluoroquinolones, Clin Infect Dis, 31, S24, 10.1086/314056 Schmitz, 1999, The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals, J Antimicrob Chemother, 43, 253, 10.1093/jac/43.2.253 Torres, 2002, Lectura interpretada del antibiograma de cocos grampositivos, Enferm Infecc Microbiol Clin, 20, 354, 10.1016/S0213-005X(02)72815-2 Jarlier, 1988, Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns, Rev Infect Dis, 10, 867, 10.1093/clinids/10.4.867 Edwards, 1998, Biological assay for the detection of metallo-β-lactamases in Bacteroides fragilis, Br J Biomed Sci, 55, 169 Tsakris, 2009, Use of boronic acid disk tests to detect extended-spectrum beta-lactamases in clinical isolates of KPC carbapenemase-possessing enterobacteriaceae, J Clin Microbiol, 47, 3420, 10.1128/JCM.01314-09 Shin, 2008, Dipicolinic acid-based disk methods for detection of metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp., Diagn Microbiol Infect Dis, 62, 102, 10.1016/j.diagmicrobio.2008.04.015 Tan, 2009, Evaluation of screening methods to detect plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, Antimicrob Agents Chemother, 53, 146, 10.1128/AAC.00862-08 Ribera, 2002, Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates, J Antimicrob Chemother, 49, 697, 10.1093/jac/49.4.697 Kaatz, 2002, Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus, J Antimicrob Chemother, 50, 833, 10.1093/jac/dkf224 Baquero, 2001, Low-level antibacterial resistance: A gateway to clinical resistance, Drug Res Updates, 4, 93, 10.1054/drup.2001.0196 Nordmann, 2009, The real threat of Klebsiella pneumoniae carbapenemase producing bacteria, Lancet Infect Dis, 9, 228, 10.1016/S1473-3099(09)70054-4 Tenover, 2000, VRSA, VISA, and GISA: The dilema behind the name game, Clin Microbiol Newletter, 22, 49, 10.1016/S0196-4399(00)88583-9 Hsu, 2008, Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections, Int J Antimicrob Agents, 32, 378, 10.1016/j.ijantimicag.2008.05.007 Novais, 2008, Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance, Antimicrob Agents Chemother, 52, 2377, 10.1128/AAC.01658-07 Sham, 1996, The role of clinical microbiology in the control and surveillance of antimicrobial resistance, ASM News, 62, 25 Chambers, 2001, The changing epidemiology of Staphylococcus aureus?, Emerging Infect Dis, 7, 178, 10.3201/eid0702.010204 Cantón, 2006, The CTX-M beta-lactamase pandemic, Curr Opin Microbiol, 9, 466, 10.1016/j.mib.2006.08.011 Coque, 2002, Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum-β-lactamases are carried by multiple Klebsiella pneumoniae clones in a single Hospital (Madrid, 1989 to 2000), Antimicrob Agents Chemother, 46, 500, 10.1128/AAC.46.2.500-510.2002 Ruiz-Garbajosa, 2009, Longer intestinal persistence of Enterococcus faecalis compared to Enterococcus faecium clones in intensive-care-unit patients, J Clin Microbiol, 47, 345, 10.1128/JCM.01597-08 Barret, 1968, Methicillin-resistant Staphylococcus aureus at Boston City Hospital: Bacteriologic and epidemiology observations, N Engl J Med, 279, 441, 10.1056/NEJM196808292790901 Kaye, 2001, Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp., Antimicrobial Agents Chemother, 45, 2628, 10.1128/AAC.45.9.2628-2630.2001 Kawalec, 2001, Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the VanB phenotype, J Clin Microbiol, 39, 4274, 10.1128/JCM.39.12.4274-4282.2001 Kollef, 2001, Is there a role for antibiotic cycling in the intensive care unit?, Crit Care Med, 29, N135, 10.1097/00003246-200104001-00014 Gerding, 2000, Antimicrobial cycling: Lessons learned from aminoglycoside experience, Infect Control Hosp Epidemiol, 21, S12, 10.1086/503168 Urban, 2000, Detection of multirresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins, Microb Drug Resist, 6, 297, 10.1089/mdr.2000.6.297 Baquero, 2003, Antibiotics, complexity, and evolution, ASM News, 69, 547 Sun, 2009, High prevalence of bla extended-spectrum beta(CTX-M)-lactamase genes in Escherichia coli isolates from pets and emergence of CTX-M-64 in China, Clin Microbiol Infect, 10.1111/j.1469-0691.2009.03127.x Drieux, 2008, Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: Review and bench guide, Clin Microbiol Infect, 14, 90, 10.1111/j.1469-0691.2007.01846.x Lina, 1999, Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci, Antimicrob Agents Chemother, 43, 1062, 10.1128/AAC.43.5.1062 De la Pedrosa, 2008, Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B), Antimicrob Agents Chemother, 52, 1964, 10.1128/AAC.01487-07 Navon-Venezia, 2005, Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting, Curr Opin Infect Dis, 18, 306, 10.1097/01.qco.0000171920.44809.f0 Aksaray, 2000, Surveillance of antimicrobial resistance among gram-negative isolates from intensive care units in eight hospitals in Turkey, J Antimicrob Chemother, 45, 695, 10.1093/jac/45.5.695 Woodford, 2007, Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory, Int J Antimicrob Agents, 29, 456, 10.1016/j.ijantimicag.2006.11.020 Walsh, 2008, Clinically significant carbapenemases: An update, Curr Opin InfectDis, 21, 367, 10.1097/QCO.0b013e328303670b